Please select the option that best describes you:

How do you address logistic barriers related to blinatumomab when treating relapsed B-ALL?   

For example, if patients are unable to receive continuous infusion from home health agencies, or if prolonged hospitalization is cost-prohibitive.  

Answer from: Medical Oncologist at Academic Institution

Answer from: at Academic Institution